SARS-CoV-2 detection using a nanobody-functionalized voltammetric device.
Diagnostic markers
Nanobiotechnology
Journal
Communications medicine
ISSN: 2730-664X
Titre abrégé: Commun Med (Lond)
Pays: England
ID NLM: 9918250414506676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
15
08
2021
accepted:
19
04
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
An ongoing need during the COVID-19 pandemic has been the requirement for accurate and efficient point-of-care testing platforms to distinguish infected from non-infected people, and to differentiate SARS-CoV-2 infections from other viruses. Electrochemical platforms can detect the virus via its envelope spike protein by recording changes in voltammetric signals between samples. However, this remains challenging due to the limited sensitivity of these sensing platforms. Here, we report on a nanobody-functionalized electrochemical platform for the rapid detection of whole SARS-CoV-2 viral particles in complex media such as saliva and nasopharyngeal swab samples. The sensor relies on the functionalization of gold electrode surface with highly-oriented Llama nanobodies specific to the spike protein receptor binding domain (RBD). The device provides results in 10 min of exposure to 200 µL of unprocessed samples with high specificity to SARS-CoV-2 viral particles in human saliva and nasopharyngeal swab samples. The developed sensor could discriminate between different human coronavirus strains and other respiratory viruses, with 90% positive and 90% negative percentage agreement on 80 clinical samples, as compared to RT-qPCR. We believe this diagnostic concept, also validated for RBD mutants and successfully tested on Delta variant samples, to be a powerful tool to detect patients' infection status, easily extendable to other viruses and capable of overcoming sensing-related mutation effects.
Sections du résumé
Background
UNASSIGNED
An ongoing need during the COVID-19 pandemic has been the requirement for accurate and efficient point-of-care testing platforms to distinguish infected from non-infected people, and to differentiate SARS-CoV-2 infections from other viruses. Electrochemical platforms can detect the virus via its envelope spike protein by recording changes in voltammetric signals between samples. However, this remains challenging due to the limited sensitivity of these sensing platforms.
Methods
UNASSIGNED
Here, we report on a nanobody-functionalized electrochemical platform for the rapid detection of whole SARS-CoV-2 viral particles in complex media such as saliva and nasopharyngeal swab samples. The sensor relies on the functionalization of gold electrode surface with highly-oriented Llama nanobodies specific to the spike protein receptor binding domain (RBD). The device provides results in 10 min of exposure to 200 µL of unprocessed samples with high specificity to SARS-CoV-2 viral particles in human saliva and nasopharyngeal swab samples.
Results
UNASSIGNED
The developed sensor could discriminate between different human coronavirus strains and other respiratory viruses, with 90% positive and 90% negative percentage agreement on 80 clinical samples, as compared to RT-qPCR.
Conclusions
UNASSIGNED
We believe this diagnostic concept, also validated for RBD mutants and successfully tested on Delta variant samples, to be a powerful tool to detect patients' infection status, easily extendable to other viruses and capable of overcoming sensing-related mutation effects.
Identifiants
pubmed: 35619829
doi: 10.1038/s43856-022-00113-8
pii: 113
pmc: PMC9126950
doi:
Types de publication
Journal Article
Langues
eng
Pagination
56Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare no competing interests.
Références
Biosens Bioelectron. 2021 Jan 1;171:112686
pubmed: 33086175
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Nat Commun. 2021 Feb 5;12(1):802
pubmed: 33547323
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Anal Chem. 2021 Jan 26;93(3):1826-1833
pubmed: 33370087
Front Immunol. 2017 Aug 21;8:977
pubmed: 28871254
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705
pubmed: 32845525
ACS Nano. 2011 Jun 28;5(6):4319-28
pubmed: 21609027
iScience. 2020 Aug 21;23(8):101406
pubmed: 32771976
ACS Appl Mater Interfaces. 2021 Apr 21;13(15):17353-17360
pubmed: 33845569
Nat Biomed Eng. 2021 Jul;5(7):666-677
pubmed: 34031558
Annu Rev Immunol. 2018 Apr 26;36:695-715
pubmed: 29490163
J Am Chem Soc. 2021 Feb 3;143(4):1722-1727
pubmed: 33481575
Biosens Bioelectron. 2021 Apr 15;178:113029
pubmed: 33515985
N Engl J Med. 2020 Sep 24;383(13):1283-1286
pubmed: 32857487
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32317257
Cell. 2020 May 28;181(5):1004-1015.e15
pubmed: 32375025
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
Microchem J. 2021 Sep;168:106445
pubmed: 34054147
Biosens Bioelectron. 2021 Nov 15;192:113497
pubmed: 34274624
Nat Struct Mol Biol. 2020 Sep;27(9):846-854
pubmed: 32661423
Biosens Bioelectron. 2021 Jan 1;171:112709
pubmed: 33075724
Annu Rev Anim Biosci. 2021 Feb 16;9:401-421
pubmed: 33233943
ACS Cent Sci. 2020 May 27;6(5):591-605
pubmed: 32382657
EClinicalMedicine. 2021 Jan;31:100677
pubmed: 33521610